Clinical Trial

A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-12-31 -> 2028-02-15 2026-05-19
minor Completion pushed: 2027-12-31 -> 2028-02-15 2026-04-21
Trial Details
NCT Number NCT07495813
Lead Sponsor Hoffmann-La Roche
Conditions Stable Coronary Artery Disease, Healthy Volunteers
Enrollment 196 participants
Start Date 2026-03-31
Primary Completion 2028-02-15 (estimated)
Study Completion 2028-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-11